An observational study For Investigating success in achieving clinical, structual and functional Remission and Sustaining efficacy with Tocilizumab
Not Applicable
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000007086
- Lead Sponsor
- niversity of Occupational and Environmental Health, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 710
Inclusion Criteria
Not provided
Exclusion Criteria
No criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentages of three different remissions; clinical remission (the disease activity score using the 28 joint count [DAS28]-ESR), structural remission (modified total Sharp score [mTSS]), and functional remission (health assessment questionnaire [HAQ] at week 104 after tocilizumab treatment.
- Secondary Outcome Measures
Name Time Method Maintenance period of clinical , structual and functional remission